Tauopathy, which has previously been implicated in the chronic pathology of TBI and other neurodegenerative diseases, may also be a target for immunotherapy27, 28, though tau pathology was not previously identified at early time points after TBI. The gene discussed is MAPT; the disease is tauopathy.